Lavender Oil, a Study Someone Read, and an $800 Budget
A staff nurse brings a single randomized trial of lavender aromatherapy for preoperative anxiety to your shared-governance meeting and proposes unit-wide adoption. She has 10 minutes on the agenda. Your unit performs about 40 same-day surgeries weekly. Several staff have asthma; one is pregnant; one patient in the past year had an anaphylactoid reaction to a scented product. The budget is $800. Nursing leadership wants a decision before the next accreditation cycle and asks you, as the clinical nurse leader, whether this is "research or a quality project."
1. How do you appraise the proposal, and how do you answer the research-versus-QI question?
Read the worked answer
Appraise the evidence, not the enthusiasm
- One trial is a starting point, not a basis for unit-wide policy. Ask: what was the comparator (usually nothing, not standard care plus attention)? Was blinding possible? What was the effect size on a validated anxiety measure, and is that difference clinically meaningful? Was the population preoperative same-day surgery like ours?
- Look for a systematic review or guideline before designing anything new. If a higher-level synthesis exists, use it; if not, that gap is the honest finding-not a mandate to adopt.
- Check safety evidence explicitly: asthma exacerbation, occupational sensitization of staff, pregnancy, and prior anaphylactoid reaction. Absence of reported harm in a small trial is not evidence of safety.
Research vs. QI
The deciding question is intent and generalizability, not the word on the form.
- If the aim is to improve care on this unit using a known intervention, with results fed back locally, that is QI-but QI still requires an ethics review pathway if you are randomizing, withholding standard care, or collecting identifiable data beyond routine practice.
- If you intend to randomize to test whether lavender reduces anxiety, and publish as generalizable knowledge, that is research and needs IRB review.
- Do not use "QI" to route around IRB review of a randomized comparison. Ask your IRB; the answer is theirs to give in writing, and it takes one email.
2. Design a defensible pilot within $800 that answers the real question without exposing staff or patients to avoidable risk.
Read the worked answer
Narrow the question
Not "is aromatherapy good?" but "for consenting adult same-day-surgery patients with no respiratory or scent sensitivity, does an offered lavender inhaler, compared with usual care, change self-reported anxiety and anti-anxiety medication use?"
Design
- Eligibility screening built into pre-op: documented asthma/COPD, known scent allergy, pregnancy, or prior reaction → not offered. Staff with asthma or pregnancy are not required to handle or be present for it; the patient-controlled inhaler removes occupational exposure as much as possible, but ventilation and proximity still need a plan.
- Consent and refusal: offered, never default. "No" requires no explanation.
- Measures: a validated anxiety scale before and after, plus PRN anxiolytic use, plus a simple acceptability question. Record adverse events, including staff symptoms, on every shift.
- Sample: a 6-week pilot at 40 patients/week with screening will still yield a small, non-generalizable sample-so frame it as a pilot, pre-specify the stopping rule (any respiratory event halts it), and do not over-interpret.
- Cost: patient-controlled inhalers and printed screening tools fit well under $800; do not buy diffusers that aerosolize into shared air.
Review: route through nursing research council and, if any randomization or identifiable data collection is planned, the IRB-before the first patient.
3. The staff nurse is enthusiastic and the budget is small. How do you lead this so the decision is credible either way, and what would success look like at 90 days?
Read the worked answer
Leadership moves
- Honor the initiative publicly. She brought evidence to shared governance-that behavior is the asset. Say so in the meeting before you say anything about the study's limits.
- Give her a real role. Ask her to lead the evidence appraisal and the pilot protocol with a mentor; ownership converts a disappointed advocate into a partner.
- Protect the skeptics. The asthmatic and pregnant staff members' concerns are data, not resistance. Name them in the meeting so they are not treated as obstruction.
- Separate the decision from the outcome. "We will run a 6-week pilot with a stopping rule and decide on the data" is a decision that does not require anyone to lose.
- Be honest about the timeline. A decision "before the next accreditation cycle" is not a clinical rationale. Say what can be known in six weeks and what cannot.
Success at 90 days
- A written IRB/QI determination, an appraisal document, and a pilot protocol filed in shared governance.
- Zero adverse events, including staff respiratory symptoms.
- Anxiety scores and PRN anxiolytic use reported as a run chart, not a single pre/post comparison.
- A clear recommendation with its uncertainty stated: adopt, adopt with limits, or stop-each acceptable, and "stop" is a legitimate success.
- Improved staff confidence that evidence questions are welcome, measurable by how many proposals come forward next quarter.
Judgment anchor: evidence-informed practice does not mean adopting the newest thing anyone read about. It means making the reasoning visible, protecting the people who bear the risk, and building a process that survives a change of staff.